Surprise: HDAC Goes Down, Not Up, in Alzheimer’s Disease
A new PET tracer belies previous results from animal models and postmortem studies. Caveat emptor for trials of HCAD inhibitors?
NEWS
Memory Slips as Soon as Amyloid Appears, Two Decades Before Dementia
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
Four Immunotherapies Now Banish Amyloid From the Brain
New data from gantenerumab and N3pG confirm that high-dose antibodies clear plaque dramatically, with manageable side effects. How will the aging brain respond?
In C9ORF72 Expansion Carriers, Protein Levels Drop in Cerebellum
A batch of new monoclonal antibodies against the C9ORF72 protein also revealed the protein lingers in presynapses.
Largest AD Whole-Exome Study to Date Finds Two New Risk Genes
A zinc-finger protein and a long noncoding RNA are now implicated in late-onset Alzheimer’s disease.
Thinning Retina … Could It Be Parkinson’s?
In early Parkinson’s disease, sparse areas on the retina correlate with dying dopaminergic neurons in the substantia nigra.
FDA Approves First RNAi Therapy
The drug, patisiran, targets messenger RNAs that cause transthyretin amyloidosis, a rare inherited neurodegenerative disease. Approval paves the way for other RNAi-based therapies.
ApoE: Common Microglial Culprit in Aging, Alzheimer’s, and Tauopathy?
Translatome profiling suggests ApoE drives a microglial gene-expression signature found in aging, Aβ amyloidosis, and tauopathy.
Virtual Exhibit Hall
Alzforum has launched a Virtual Exhibit Hall, a place for companies to showcase their initatives, products, and services. We welcome our exhibitors - Biogen, BioLegend, Nanostring Technologies, Inc., and The Jackson Laboratory and encourage our readers to explore their virtual booths here.
SPOTLIGHT
Ups and Downs of Amyloid
At AAIC 2018, researchers presented the latest data on the anti-amyloid antibodies gantenerumab and N3pG. Bottom line: Both clean out plaques, bringing many people below the threshold for amyloid positivity within six months to two years. Other researchers focused on amyloid accumulation, reporting that even subthreshold levels associate with memory decline. This early decline can be detected on sensitive cognitive composites, enabling ever-earlier preclinical trials. Whether amyloid removal will slow cognitive decline remains to be seen, however.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- Total Items: 348
-
Jobs
- New Items: 7
- Total Items: 75
-
Conference Calendar
- Total Items: 67
- Member Directory
Latest Comments